Article: Sirion Therapeutics to merge with Sytera.(biopharmaceutical firm )(Brief article)

Article: Sirion launches Durezol in USA.(Sirion ...
Pharma Marketletter;  October 13, 2008 ;     584 words ...Sirion Therapeutics, a privately-held US ophthalmic-focused biopharmaceutical firm, has launched Durezol (difluprednate ophthalmic emulsion) after it was approved by the Food and Drug Administration in June ...

Article: Sirion Therapeutics Merges With Sytera to Develop ...
PR Newswire;  August 16, 2006 ;     700+ words ... ... PRNewswire/ -- Sirion Therapeutics, Inc., an ... Sytera, Inc., a biopharmaceutical firm based in La Jolla ... will be named Sirion Therapeutics, Inc., and ... member of the Sirion Therapeutics Board of Directors ...

Article: Tenby Pharma emerges with $25M financing.(Tenby ...
Pharma Marketletter;  September 25, 2006 ;     700+ words ... ... announced its acquisition of Sirion Therapeutics as a wholly-owned subsidiary ... chief medical officer of Sirion Therapeutics, and Barry Butler have ... Sirion acquired Sytera, a biopharmaceutical firm and, in August, it bought ...

Article: Sirion Therapeutics Acquires Worldwide License to ...
PR Newswire;  February 20, 2008 ;     700+ words ... ... Feb. 20 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ... Chief Medical Officer of Sirion Therapeutics. Under the terms of this licensing agreement, Sirion Therapeutics will have the rights to manufacture ...

Article: Sirion Therapeutics, Inc. Combines With Tenby ...
PR Newswire;  September 18, 2006 ;     700+ words ... ... announced today its acquisition of Sirion Therapeutics, Inc. as a wholly owned subsidiary ... Barry Butler, President and CEO of Sirion Therapeutics, Inc., has been appointed to ... MD, Chief Medical Officer of Sirion Therapeutics, and Barry Butler have been appointed ...

Article: Sirion Therapeutics Preclinical Studies: Two New ...
PR Newswire;  April 21, 2008 ;     700+ words ... ... April 21 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic ... Barry Butler, President and CEO of Sirion Therapeutics, Inc. "Sirion's targeted research ... Durezol(TM) is the trademark of Sirion Therapeutics, Inc. and is currently under review ...

Article: Sirion Therapeutics Announces Clinical Data to be ...
PR Newswire;  April 23, 2007 ;     700+ words ... ... April 23 /PRNewswire/ -- Sirion Therapeutics announced today that data on two ... President and Chief Executive Officer of Sirion Therapeutics. "This is exciting news for our ... ophthalmic therapies for unmet needs." Sirion Therapeutics Reception for all ARVO attendees ...